Emily Smith
Family · Chester, VANPI 1720751159
Payments from drug & device makers
Across 289 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$939
- Pfizer$848
- AstraZeneca$696
- AbbVie$419
- Lilly USA, LLC$415
- Exact Sciences$265
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,112100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 53 | $939 |
| Pfizer | 47 | $848 |
| AstraZeneca(2 entities) | 39 | $696 |
| AbbVie | 31 | $419 |
| Lilly USA, LLC | 24 | $415 |
| Exact Sciences | 13 | $265 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $202 |
| Amgen | 9 | $153 |
| Abbott | 6 | $109 |
| Actelion Pharmaceuticals US, Inc. | 6 | $104 |
| Boehringer Ingelheim | 6 | $102 |
| Bayer | 5 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $72 |
| Shield Therapeutics Inc | 1 | $60 |
| Dexcom, Inc. | 3 | $58 |
| GSK | 3 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $55 |
| Dynavax Technologies Corporation | 2 | $52 |
| Merck | 2 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Edwards Lifesciences | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
| Novartis | 2 | $37 |
| Astellas Pharma US Inc | 2 | $33 |
| Johnson & Johnson | 2 | $30 |
| Avanir Pharmaceuticals, Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Cequr Corporation | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Impulse Dynamics (USA) Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$5,129 in reported general payments places this provider in the 90th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 118 | $198,819 |
| JardianceEmpagliflozin | 62 | $59,981 |
| FarxigaDapagliflozin Propanediol | 20 | $28,996 |
| XareltoRivaroxaban | 18 | $27,147 |
| TrulicityDulaglutide | 11 | $24,838 |
| JanuviaSitagliptin Phosphate | 20 | $22,501 |
| EliquisApixaban | 13 | $22,106 |
| MounjaroTirzepatide | 14 | $21,835 |
| RybelsusSemaglutide | 11 | $16,601 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $13,068 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $12,234 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,251 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $4,397 |
| Atorvastatin Calcium | 597 | $4,160 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 39 | $4,132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $939 | $215,419129 claims |
| Boehringer IngelheimJardiance | $102 | $59,98162 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $696 | $50,48163 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $415 | $46,67325 claims |
| Johnson & JohnsonXarelto | $30 | $27,14718 claims |
| MerckJanuvia | $51 | $22,50120 claims |
| PfizerEliquis | $848 | $22,10613 claims |
| GSKTrelegy Ellipta | $57 | $13,06812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,332 family providers in Virginia.
Other family in Chester
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
- Norman JacobowitzManassas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.